Jeil Pharmaceutical Co Ltd

271980 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

8,800.00KRW-20.00 (-0.23%)

Price History

Full chart

Market Stats

Previous Close8,820.00

Open8,810.00

Day Range8,710.00 – 8,950.00

52-Week Range8,810.00 – 19,290.00

Volume8.05K

Market Cap147.20B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.60

50-Day Avg10,103.80

200-Day Avg12,619.80

About

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees947
Headquarters343, Sapyeong-daero, Seoul, South Korea, 06543, Korea
Websitehttps://www.jeilpharm.co.kr

Financials

Income Statement

Currency: KRW	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	371.59B	627.07B	671.41B	691.32B	700.69B	722.23B	726.39B	704.54B	567.24B
Growth (%)	-	+68.75%	+7.07%	+2.97%	+1.36%	+3.07%	+0.58%	-3.01%	-19.49%
Cost of Revenue	294.55B	488.44B	519.48B	534.63B	544.72B	565.43B	542.14B	527.05B	354.34B
Gross Profit	77.04B	138.63B	151.92B	156.69B	155.98B	156.80B	184.26B	177.49B	212.90B
Gross Margin	20.73%	22.11%	22.63%	22.67%	22.26%	21.71%	25.37%	25.19%	37.53%
Operating Expense	72.07B	131.24B	151.55B	143.79B	166.36B	170.13B	175.37B	196.04B	191.91B
Operating Income	4.97B	7.39B	375.11M	12.90B	-10.38B	-13.33B	8.89B	-18.55B	21.00B
Operating Margin	1.34%	1.18%	0.06%	1.87%	-1.48%	-1.85%	1.22%	-2.63%	3.70%
EBITDA	8.23B	13.11B	7.88B	22.62B	-2.73B	-1.35B	17.72B	-10.61B	51.66B
EBITDA Margin	2.21%	2.09%	1.17%	3.27%	-0.39%	-0.19%	2.44%	-1.51%	9.11%
Net Income	1.07B	1.89B	-10.58B	6.92B	-12.47B	-13.09B	5.00B	-29.97B	23.38B
Net Income Margin	0.29%	0.30%	-1.58%	1.00%	-1.78%	-1.81%	0.69%	-4.25%	4.12%
R&D	13.51B	24.88B	22.11B	24.27B	38.97B	41.15B	45.73B	38.77B	44.97B
R&D as % of Total Revenue	3.63%	3.97%	3.29%	3.51%	5.56%	5.70%	6.30%	5.50%	7.93%
Interest Expense	0	1.60B	1.21B	1.07B	1.97B	3.01B	6.03B	5.06B	4.39B
Interest Expense % of Total Revenue	0.00%	0.25%	0.18%	0.15%	0.28%	0.42%	0.83%	0.72%	0.77%

Balance Sheet

Currency: KRW	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	413.73B	402.90B	401.59B	409.66B	426.49B	456.89B	487.33B	525.70B	510.57B
Total Liabilities	235.74B	217.97B	231.54B	237.18B	259.14B	301.29B	330.29B	306.38B	259.55B
Total Equity	177.99B	184.93B	170.04B	172.39B	168.21B	157.91B	158.57B	188.15B	211.07B
Cash	16.21B	2.50B	13.52B	3.89B	25.96B	31.45B	32.99B	53.48B	48.87B
Net Debt	45.61B	35.38B	12.39B	40.31B	5.86B	11.63B	31.78B	17.52B	41.61B

Cash Flow

Currency: KRW	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-4.21B	21.45B	28.96B	-19.05B	19.10B	-15.15B	-4.98B	3.21B	-5.69B
Investing Cash Flow	-13.11B	-10.41B	-1.15B	-5.58B	-8.04B	-	-	-	-
Financing Cash Flow	25.73B	-24.75B	-16.59B	15.13B	11.07B	-	-	-	-
Capital Expenditure	4.00B	10.29B	1.09B	2.41B	5.34B	16.96B	9.58B	6.61B	9.08B
Free Cash Flow	-8.21B	11.17B	27.56B	-21.91B	13.71B	-32.11B	-14.56B	-3.40B	-14.77B
Dividends Paid	734.83M	734.83M	875.45M	1.02B	1.02B	947.74M	728.38M	728.38M	-
FCF to OCF	194.98%	52.05%	95.18%	115.05%	71.77%	211.96%	292.26%	-105.82%	259.54%
Dividend Paid to FCF	-8.95%	6.58%	3.18%	-4.67%	7.46%	-2.95%	-5.00%	-21.42%	-

Earnings

Report Date	Sep 30, 2017	Dec 31, 2017	Mar 31, 2018	Jun 30, 2018	Sep 30, 2018	Dec 31, 2018	Mar 31, 2019	Jun 30, 2019	Sep 30, 2019	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sep 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	33.44	24.52	23.37	12.72	36.27	56.14	23.45	136.10	82.41	-962.68	261.33	163.64	29.42	18.84	-90.05	18.30	-24.31	-759.00	-268.85	-120.81	-260.97	-247.13	871.74	-92.61	-282.13	-153.53	-197.50	-1819.49	-288.03	248.42	179.77	214.12	705.48	505.40	-21.19	-545.23
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap147.20B

Enterprise Value191.48B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.27

Price / Book0.71

Revenue (TTM)543.49B

Gross Profit (TTM)220.03B

EBITDA16.94B

Profit Margin1.71%

Operating Margin-4.80%

Return on Equity9.11%

Return on Assets0.50%

Shares Outstanding14.70M

Shares Float5.44M

Beta0.60

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20231×

50.00Dec 27, 2023

20221×

50.00Dec 28, 2022

20211×

65.00Dec 29, 2021

20201×

70.00Dec 29, 2020

20191×

70.00Dec 27, 2019

20181×

60.00Dec 27, 2018

20171×

50.00Dec 27, 2017

Stock Splits

Apr 11, 20181.4:1